Advice
Following a full submission
sunitinib (Sutent®) is not recommended for use within NHS Scotland for the treatment of advanced and/or metastatic renal cell carcinoma (MRCC). In a planned interim analysis, sunitinib improved progression-free survival and objective response rate when compared with interferon alfa. However, as yet there is insufficient information available on overall survival.
The manufacturer did not present a sufficiently robust economic analysis and their justification of the treatment’s cost in relation to its health benefits was not sufficient to gain acceptance by SMC.
The licence holder has indicated their decision to resubmit.
Download detailed advice79KB (PDF)
Medicine details
- Medicine name:
- sunitinib 12.5mg, 25mg, 50mg capsules (Sutent)
- SMC ID:
- 384/07
- Indication:
- First line treatment of advanced and/or metastatic renal cell carcinoma (MRCC)
- Pharmaceutical company
- Pfizer Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Superseded
- Date advice published
- 09 July 2007